Objective Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly. The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB. The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises. Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies. In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally. Fields of science social sciencessociologydemographymortalitysocial sciencessociologysocial issuessocial inequalitiesmedical and health sciencesclinical medicinepneumologytuberculosisengineering and technologymedical engineeringmedical laboratory technologydiagnostic technologiesengineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-2-2014 Funding Scheme SME-2 - SME instrument phase 2 Coordinator PROTEINLOGIC LIMITED Net EU contribution € 3 031 548,69 Address SHAKESPEARE HOUSE 42 NEWMARKET ROAD CB5 8EP CAMBRIDGE CAMBRIDGESHIRE United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region East of England East Anglia Cambridgeshire CC Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 337 196,50 Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all BIOSENSIA LIMITED Participation ended Ireland Net EU contribution € 551 847,31 Address UNIT 1 16 NOVA UCD UNIVERSITY COLLEGE DUBLIN BELFIELD 4 DUBLIN See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 556 111,00
